A study using angiopoietin 2-induced cardiac hypertrophy mice noted that FGF21 treatment increased SIRT1 deacetylation activity, promoted AMPK phosphorylation, and reduced cardiac hypertrophy in a SIRT1-dependent pathway (55). Here, FGF21 is linked to cardiac hypertrophy.